A fast test to identify bloodstream infections directly from blood samples
An automated culture-free system for the identification of bloodstream infections direct from blood
This study is working on a new test that can quickly find infections in your blood in just four hours, instead of the usual days, so you can get the right treatment faster, even if you've already had antibiotics.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Helixbind, INC. NIH-funded |
| Lab location | 1 site (Boxborough, UNITED STATES) |
| Project ID | NIH-11005928 on NIH RePORTER |
What this research studies
This research focuses on developing a rapid diagnostic test that can identify bloodstream infections (BSIs) directly from blood samples without the need for traditional blood cultures. The current method can take 1-3 days to yield results, which delays treatment and can lead to severe complications. The new test, called RaPID/BSI, aims to provide results in just four hours, allowing for quicker and more accurate identification of bacterial and fungal pathogens. This innovation is particularly beneficial as it remains effective even when patients have received prior antimicrobial treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suspected of having bloodstream infections, particularly those who may be experiencing sepsis.
Not a fit: Patients who do not have bloodstream infections or those who are not hospitalized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the time to diagnosis and improve treatment outcomes for patients with bloodstream infections.
How similar studies have performed: Other research has shown promise in developing rapid diagnostic tests for infections, indicating a potential for success with this novel approach.
Where this research is happening
Boxborough, UNITED STATES
- Helixbind, INC. — Boxborough, United States (Active)
Researchers
- Principal investigator: Singer, Alon — Helixbind, INC.
- Study coordinator: Singer, Alon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.